Skip to main content

rosiglitazone

Generic: ROSIGLITAZONE MALEATE·Brand: AVANDIA, ROSIGLITAZONE MALEATE

rosiglitazone: developed by 1 company · 1 clinical trial tracked · 1 FDA decision.

rosiglitazone evidence translation

What we can confirm

1 FDA record · 1 tracked trial

What it means

Source-backed records connect rosiglitazone to TEVA; that link alone does not prove the drug works.

What to watch

Watch active trials and any change in FDA or trial status.
BioSniper AIPage evidence connected

Prepared research question

How could rosiglitazone → TEVA affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors

Related indications

Advanced Solid Tumors
Development Pipeline (1)
CompanyPhase
Teva Pharmaceutical Industries Limited (TEVA)Approved
Clinical Trials (1)

A Phase 1, Open-label, 2-part, Drug-Drug Interaction Study to Evaluate the Effects of Multiple Oral Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

NCT07372625·Phase 1·PMVP
Recruiting

Primary endpoint: Metformin Cmax geometric mean ratio

Interventionalopen14 targetStarted 2026-02Completion 2028-015 sites · United StatesPMV Pharmaceuticals, Inc
FDA Decisions1 records
Approval(TEVA)FDA ↗
ANDA077337OralTablet

Frequently asked questions

Who is developing rosiglitazone?

rosiglitazone is being developed by Teva Pharmaceutical Industries Limited.

How many clinical trials involve rosiglitazone?

BioSniper tracks 1 clinical trial involving rosiglitazone.

What is rosiglitazone's latest FDA decision?

The most recent tracked FDA decision for rosiglitazone is Approval, dated May 19, 2017.